KALA BIO, Inc. (KALA) - Dilution Analysis

8-K filing: Stock split 1-for-50 | Outstanding: 27,849,725 → 18,589,832

S-3 filing: Kala Bio, Inc. is filing an S-3 form to offer and sell common stock, preferred stock, debt securities, warrants, and subscription rights up to an aggregate amount of $350,000,000.

10-K filing | 27.8M shares outstanding

8-K filing: On November 24, 2025, the Company closed the first tranche of a private placement with David Lazar, issuing 900,000 Series AA Preferred Shares at $2.00 per share for gross proceeds of $1.8 million. ($1.8M proceeds)

8-K filing: KALA BIO, Inc. completed a registered direct offering, issuing 900,000 shares of common stock and pre-funded warrants to purchase up to 9,100,000 additional shares at $1.00 per share, resulting in gross proceeds of $10 million before fees. ($10.0M proceeds)

8-K filing: The Company entered into a Securities Purchase Agreement to issue Series AA and Series AAA Preferred Stock for gross proceeds of up to $6.0 million, issued 900,000 Series AA Preferred Shares at $2.00 per share for $1.8 million in gross proceeds in a first closing, and agreed to issue 1,620,000 shares of common stock to Oxford as part of a loan settlement. ($1.8M proceeds)

10-Q filing | 7.0M shares outstanding

10-Q filing | 6.5M shares outstanding

10-Q filing | 6.3M shares outstanding

10-K filing | 6.1M shares outstanding

S-3 filing: This prospectus relates to the resale from time to time of up to 1,669,203 shares of common stock of KALA BIO, Inc. by the selling stockholders.

8-K filing: KALA BIO, Inc. entered into a Securities Purchase Agreement to issue and sell Common Shares and Series I Convertible Non-Redeemable Preferred Stock in a private placement for gross proceeds of approximately $10.75 million, with 1,340,603 Common Shares issued at $6.44 per share and 3,286 Preferred Shares issued at $644.00 per share.

10-Q filing | 4.6M shares outstanding

10-Q filing | 4.6M shares outstanding

S-3 filing: This S-3 filing relates to the resale from time to time of up to 3,519,514 shares of common stock of KALA BIO, Inc. by the selling stockholders.

8-K filing: KALA BIO, Inc. entered into a Securities Purchase Agreement to issue and sell common stock and Series H Convertible Non-Redeemable Preferred Stock in a private placement for gross proceeds of approximately $12.5 million, with the closing expected on or about June 28, 2024, and expects to have 4,458,909 shares of Common Stock outstanding upon closing.

10-Q filing | 2.8M shares outstanding

10-K filing | 2.8M shares outstanding

8-K filing: KALA BIO, Inc. entered into a Securities Purchase Agreement to issue and sell 10,901 shares of Series G Convertible Non-Redeemable Preferred Stock at $788.90 per share for gross proceeds of approximately $8.6 million in a private placement. ($8.6M proceeds)

8-K filing: KALA BIO, Inc. entered into a Securities Purchase Agreement to issue and sell 2,928 shares of Series F Convertible Non-Redeemable Preferred Stock at $683.00 per share for gross proceeds of approximately $2.0 million in a private placement. ($2.0M proceeds)

10-Q filing | 2.6M shares outstanding

10-Q filing | 2.4M shares outstanding

10-Q filing | 2.3M shares outstanding

S-3/A filing: Kala Pharmaceuticals may offer and sell securities from time to time in one or more offerings of up to $350,000,000 in aggregate offering price.

10-K filing | 1.7M shares outstanding

S-3 filing: Kala Pharmaceuticals files an S-3 to offer debt securities, common stock, preferred stock, depositary shares, subscription rights, units and warrants from time to time with an aggregate offering price of up to $350,000,000. They are also offering common stock in an at the market offering with Jefferies as the sales agent for up to $40,000,000.

S-3 filing: This S-3 filing is for the resale of up to 5,391,213 shares of common stock by selling stockholders, including shares issuable upon conversion of Series E Preferred Stock.

8-K filing: Kala Pharmaceuticals entered into an Open Market Sale AgreementSM with Jefferies LLC, as agent, to offer and sell shares of its common stock from time to time, and the company completed the sale of $75.0 million of its shares of Common Stock pursuant to a prior sales agreement. ($86.0M proceeds)

8-K filing: Kala Pharmaceuticals, Inc. entered into a loan amendment with Oxford Finance LLC, and completed a second closing of a private placement issuing preferred shares for gross proceeds of approximately $25.0 million. ($31.0M proceeds)

10-Q filing | 1.5M shares outstanding

8-K filing: Kala Pharmaceuticals declared a dividend of Series D Preferred Stock for each outstanding share of common stock and approved an amendment to the bylaws lowering the quorum requirement.

10-Q filing | 73.7M shares outstanding

10-Q filing | 73.6M shares outstanding

10-K filing | 65.2M shares outstanding

10-Q filing | 65.1M shares outstanding

8-K filing: Kala Pharmaceuticals, Inc. acquired Combangio, Inc. through a merger, issuing 7,788,667 shares of common stock to Combangio equityholders as part of the consideration, with an upfront cash payment of $5.0 million. ($16.12M proceeds)

10-Q filing | 64.8M shares outstanding

10-Q filing | 63.8M shares outstanding

10-K filing | 58.9M shares outstanding

8-K filing: Kala Pharmaceuticals reports preliminary cash, cash equivalents, and short-term investments of approximately $153.5 million as of December 31, 2020, including net proceeds from the sale of common stock under its at-the-market offering program during Q4 2020, where 2,821,059 shares were sold for net proceeds of $20.6 million.

10-Q filing | 56.1M shares outstanding

10-Q filing | 55.8M shares outstanding

S-3 filing: The company intends to offer and sell securities from time to time in one or more offerings of up to $350,000,000 in aggregate offering price.

10-Q filing | 55.7M shares outstanding

8-K filing: Kala Pharmaceuticals, Inc. entered into an underwriting agreement for a public offering of 16,000,000 shares of common stock at $7.89 per share, with an option for the underwriters to purchase an additional 2,400,000 shares. ($118.3M proceeds)

10-K filing | 36.8M shares outstanding